Our Work
Latham & Watkins Advises on IO Biotech’s US$75 Million Private Placement Financing
August 7, 2023
Firm represents the placement agents in the financing.
IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, has announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately US$75 million, before deducting offering expenses.
Latham & Watkins LLP advised the placement agents in the private placement with a New York capital markets team led by partners Nathan Ajiashvili and Alison Haggerty, with associates Kathleen Mehary, Angel Marcial, and Erin Gilgen.